Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Main Capital and Alfa eCare in connection with their strategic acquisition of Clinicbuddy
Mandate

Vinge has advised Main Capital and Alfa eCare in connection with their strategic acquisition of Clinicbuddy

June 22, 2021 Employment and Benefits M&A IT, Telecommunications and Outsourcing Commercial Agreements

The Alfa eCare group is a recognized eHealth software company, providing solutions to both public and private healthcare providers throughout Sweden.

Clinicbuddy provides various software solutions for care planning and digitization within healthcare, such as digital medical records and booking systems. The company’s products contribute to safe record keeping for care providers and more efficient and flexible systems for different types of clinics.

Vinge’s team consisted of Filip Öhrner, Kristina Ekberg and Eléonore Friberg (M&A), Ebba Svenburg (Employment), Karl-Hugo Engdahl (GDPR/IT), Rebecka Weitzberg (IP), Lisa Hörnqvist (Agreements) and Sara Dahlros Sköld (VDR).

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025